China rejects patent on hepatitis C drug sofosbuvir


Shandong Sihuan Pharmaceutical Co.,Ltd.
Add :Nanyuan Road, Economic Development Zone,Pingyuan County, Dezhou City,Shandong Province, China. 
Tel:+86-531-89702887 +86-531-88993983 +86-531-88993893

Webpage Copyright:Shandong Sihuan Pharmaceutical Co.,Ltd.  |  ICP Register No.: 鲁ICP备17046678号-1 | Powered by JINAN

China rejects patent on hepatitis C drug sofosbuvir

Page view

The Chinese patent office has rejected a patent application for the blockbuster hepatitis C treatment sofosbuvir, increasing the possibility of a generic version of the drug to become available in China.

The decision comes after a challenge by the Initiative for Medicines, Access and Knowledge (I-MAK), a US based group that campaigns for better access to affordable drugs. The group claimed that Gilead Sciences, the US biotechnology company that makes sofosbuvir, which recorded sales of more than $10bn in 2014, was seeking “illegitimate patents” for sofosbuvir and "blocking millions".